Condition: Metastatic Melanoma · Unresectable Melanoma · Melanoma · Sponsor: Iovance Biotherapeutics, Inc.
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
This description comes directly from the study's public registry record.
Iovance Biotherapeutics https://www.tilvance-301.com · 1-844-845-4682 · Clinical.Inquiries@iovance.com
Iovance Biotherapeutics Study Team · 1-844-845-4682 · Clinical.Inquiries@iovance.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham: The Kirklin Clinic | Birmingham, Alabama, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| California Pacific Medical Center | San Francisco, California, United States | Recruiting |
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
| University of Illinois Hospital & Health Sciences System | Chicago, Illinois, United States | Withdrawn |
| University of Kansas | Kansas City, Kansas, United States | Withdrawn |
| University of Louisville - James Graham Brown Cancer Center | Louisville, Kentucky, United States | Withdrawn |
| National Cancer Institute | Bethesda, Maryland, United States | Recruiting |
| Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center | Detroit, Michigan, United States | Withdrawn |
| Henry Ford Health | Detroit, Michigan, United States | Recruiting |
+ 69 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05727904